Steven Cohen’s Adaptive Biotechnologies ADPT Stock Holding History

Steven Cohen’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,021,808	Closed	-$14.2M	–	3936
2026 Q1	$14.2M	Buy	1,021,808 +818,733	+403%	+$13M	0.02%	1015
2025 Q4	$3.3M	Sell	203,075 -116,396	-36%	-$1.9M	﹤0.01%	2135
2025 Q3	$4.78M	Sell	319,471 -1,054,452	-77%	-$12.8M	0.01%	1089
2025 Q2	$16M	Buy	+1,373,923	New	+$12.5M	0.03%	576
2025 Q1	–	Sell	-937,331	Closed	-$5.62M	–	1994
2024 Q4	$5.62M	Buy	937,331 +441,839	+89%	+$2.44M	0.01%	911
2024 Q3	$2.54M	Buy	+495,492	New	+$2.16M	0.01%	1097
2024 Q2	–	Sell	-274,700	Closed	-$882K	–	1804
2024 Q1	$882K	Sell	274,700 -3,447,800	-93%	-$13.3M	﹤0.01%	1489
2023 Q4	$18.2M	Sell	3,722,500 -1,990,800	-35%	-$9.08M	0.04%	465
2023 Q3	$31.1M	Buy	+5,713,300	New	+$37.8M	0.09%	286
2019 Q3	–	Sell	-50,000	Closed	-$2.42M	–	1096
2019 Q2	$2.42M	Buy	+50,000	New	+$2.21M	0.01%	631

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Steven Cohen's ADPT Position: Q2 2026 in Review

Steven Cohen sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 1,021,808 shares — an estimated $14.2M sold.

Steven Cohen first reported a position in ADPT in Q2 2019 and held it in 10 quarters. The position peaked at $31.1M in Q3 2023. 298 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Steven Cohen reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 1,021,808 Adaptive Biotechnologies shares in Q2 2026, an estimated $14.2M.
Steven Cohen first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 10 quarters.
Steven Cohen's Adaptive Biotechnologies position peaked at $31.1M in Q3 2023.
298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.